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Abstract
Introduction: Circulating tumor cells (CTC) have been recently proposed as a new dynamic blood marker whose
positivity at baseline is a prognostic factor and whose changes under treatment are correlated with progression-
free survival (PFS) in metastatic breast cancer patients. However, serum marker levels are also used for the same
purpose, and no clear comparison has been reported to date.
Methods: The IC 2006-04 enrolled prospectively 267 metastatic breast cancer patients treated by first line
chemotherapy and confirmed that CTC levels are an independent prognostic factor for PFS and overall survival (OS). A
secondary pre-planned endpoint was to compare prospectively the positivity rates and the value of CTC (CellSearch®),
of serum tumor markers (carcinoembryonic antigen (CEA), cancer antigen 15.3 (CA 15-3), CYFRA 21-1), and of serum
non-tumor markers (lactate deshydrogenase (LDH), alkaline phosphatase (ALP)) at baseline and under treatment for PFS
prediction, independently from the other known prognostic factors, using univariate analyses and concordance indexes.
Results: A total of 90% of the patients had at least one elevated blood marker. Blood markers were correlated with
poor performance status, high number of metastatic sites and with each other. In particular, CYFRA 21-1, a marker
usually used in lung cancer, was elevated in 65% of patients. A total of 86% of patients had either CA 15-3 and/or
CYFRA 21-1 elevated at baseline. Each serum marker was associated, when elevated at baseline, with a significantly
shorter PFS. Serum marker changes during treatment, assessed either between baseline and week 3 or between
baseline and weeks 6 to 9, were significantly associated with PFS, as reported for CTC. Concordance indexes
comparison showed no clear superiority of any of the serum marker or CTC for PFS prediction.
Conclusions: For the purpose of PFS prediction by measuring blood marker changes during treatment, currently
available blood-derived markers (CTC and serum markers) had globally similar performances. Besides CEA and CA
15-3, CYFRA 21-1 is commonly elevated in metastatic breast cancer and has a strong prognostic value.
Introduction
Several serum markers have been developed in different
types of cancer as tools for non-invasive assessment of
the tumor burden, mostly in metastatic patients. Quanti-
tative variations of serum markers are, therefore, often
used in several cancer types as noninvasive tools to
assess treatment efficiency in metastatic patients. How-
ever, the use of serum tumor markers faces several
issues and unanswered questions: their specificity and
sensitivity are considered as low and no clear consensus
exists on what threshold and/or variation should be
considered clinically significant and which serum marker
to follow.
In breast cancer, the commonly used serum markers
are carcinoembryonic antigen (CEA), cancer antigen
27.29 (CA 27.29), and cancer antigen 15.3 (CA 15-3)
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[1]. CEA is a cell surface glycoprotein involved in cell
adhesion, normally not present in the blood of healthy
adults. CA 27.29, mostly used in North America, and
CA 15-3, mostly used in Europe, correspond to two dif-
ferent epitopes of the same protein, MUC1, which is
also a cell surface glycoprotein involved in cell adhesion.
CYFRA 21-1, which is a commonly used serum marker
in lung cancer [2], consists of cytokeratin-19 fragments
which are specifically recognized by two monoclonal
antibodies originally derived after injecting breast cancer
cells (MCF7 cell line) into mice [3]. Small published
reports, together with an empiric background at the
Institut Curie, suggested that CYFRA 21-1 is commonly
elevated and may be used for the management of meta-
static breast cancers [4,5]. The 2007 American Society
of Clinical Oncology update on tumor markers in breast
cancer [6] reported that for monitoring patients with
metastatic disease during therapy, CA 27.29 or CA 15-3
can be used in conjunction with other monitoring tools,
such as tumor response radiological assessment.
In 2004, circulating tumor cells (CTC) detection in
blood by the CellSearch® system (Veridex, Raritan NJ,
USA) was reported to be a prognostic marker in a study
by Cristofanilli et al. [7]; moreover, changes in CTC
count after one cycle of chemotherapy were associated
with progression-free survival (PFS) [8]. On the basis of
this first study, the FDA cleared the use of the Cell-
Search® system as a tool for monitoring chemotherapy
in metastatic breast cancer patients, although no com-
parison with serum marker was initially reported. The
prospective multicentric IC 2006-04 study was initiated
in 2006 as a confirmatory study of the Cristofanilli’s
study, with the correlation of CTC changes and survival
as the primary objective. We have recently reported this
confirmatory objective of the study, which was clearly
reached: CTC changes are a strong prognostic factor for
both PFS and overall survival (OS) [9]. We report here,
for the first time, the comparison of CTC with different
serum tumor markers (CEA, CA 15-3, CYFRA 21-1)
and non-tumor markers (lactate deshydrogenase LDH,
alkaline phosphatase ALP), which was a prospectively
planned secondary objective of the IC 2006-04 study.
Materials and methods
This prospective study was approved by the national
ethics board, identified as DGS 2006-A00523-48
(France) and NCT00898014 (USA) and was conducted
in five different French comprehensive cancer centers.
Patients and treatment
The main eligibility requirements for this study included
the patient’s written informed consent, metastatic breast
cancer, patients entering first-line chemotherapy (chosen
by clinicians) with or without targeted therapy, life
expectancy of at least three months, and measurable or
evaluable disease. Clinical evaluations were conducted as
usual, but were mandatory at inclusion (before cycle 1,
that is, week 0) and at the first radiological evaluation
before cycle 3 or 4 (C3/4, that is, weeks 6 to 9). Radiolo-
gical evaluations (RECIST [10]) were mandatory at
inclusion and before C3/4. The following blood tests
were obtained at inclusion, before cycle 2 (C2), C3/4,
and at progression: complete blood count, liver function
(including LDH and ALP), serum calcium and serum
markers: CEA, CA 15-3 and CYFRA 21-1. These blood
tests were processed locally and disclosed to clinicians.
CTC were analyzed at four different time-points in an
experienced laboratory (Institut Curie, Paris): at inclu-
sion (before starting treatment), before C2, before C3/4
and at disease progression (not shown). CTC counts
were not disclosed to clinicians. Technical details of the
CellSearch® technique have been described elsewhere
[11].
Objectives and statistics
The study was powered for its main objective that con-
sisted of detecting among patients with ≥ 5 CTC/7.5 ml
at baseline, a 35% difference in six-month PFS rates
between patients with a CTC count < or ≥ 5 CTC/7.5
ml before C2. The study was not specially powered for
its planned secondary objectives, including this compari-
son with serum tumor markers. Data are expressed as
means or numbers (%). Categorical variables were com-
pared by chi-square or Fisher’s exact test, and continu-
ous variables were compared by Student’s t-test or
Wilcoxon’s rank-sum test. Kaplan-Meier progression
free survival (PFS) curves were computed according to
CTC counts (< or ≥ 5 CTC/7.5 ml) and other tumor
markers (< or ≥ Upper Limit of Normal Value (ULNV)),
and were compared using log-rank tests. Progression
was defined as local or distant relapse or death by any
cause. Concordance index was also computed for each
marker as continuous variables, PFS as outcome. Uni-
variate analysis was performed using hazard ratios and
95% CI for PFS for each clinical characteristic and for
each tumor marker or CTCs separately. A concordance
index for PFS based on a clinical model (a model
including all the above clinical characteristics) was used
to show by how much each tumor marker or CTCs
improved the performance of the clinical model in a
multivariate analysis. Significance was defined as P ≤
0.05. Statistical analyses were performed using R2.12.1
software (Wien University, Wien, Austria)[12]
Results
From June 2007 to September 2009, 267 patients with a
median age of 57 years were included in the IC 2006-04
study. With a median follow-up of 14.9 months, 161
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tumor progressions (60%) were recorded at the time of
analysis.
Detection rates at baseline
CTC and serum marker values at inclusion repartition
in percentile, mean, median range are given in Table 1
and Figure 1. Values for serum markers are expressed in
ULNV: upper limit of normal value. Table 2 shows ele-
vated serum marker (> ULNV) and CTC (≥ 5 CTC/ml)
incidence rates at baseline: CA 15-3 and CYFRA 21-1
were the two most commonly elevated serum markers.
Serum markers and CTC were highly correlated to per-
formance status, number of metastatic sites and to each
other. Table 3 shows the percentage of patients who
had at least one marker elevated at baseline according
to different marker combinations. As expected, this per-
centage globally increases with the number of markers
assessed. However, the combination of CA 15-3 and
CYFRA 21-1 retrieved almost the same positivity rate
(86%) than all four markers (90%).
Single assessment and association with PFS
When elevated, all markers tested at baseline had a
negative prognostic impact in univariate analysis, as
shown in Figure 2. The concordance index (and 95%
confidence interval), which quantifies the quality of
ranking and is a common performance measure for
assessing learned models in survival analysis, was calcu-
lated for each marker, with PFS as the outcome. Con-
cordance indexes with PFS were, at baseline, C-indexALP
= 0.56 (0.50 to 0.61) (n = 238), C-indexCA15-3 = 0.56
(0.51 to 0.61) (n = 244), C-indexCEA = 0.58 (0.52 to
0.64) (n = 210), C-indexCTC = 0.61 (0.56 to 0.66) (n =
257), C-indexCYFRA21-1 = 0.67 (0.62 to 0.72) (n = 190)
and C-indexLDH = 0.68 (0.63 to 0.73) (n = 218). These
results showed that the markers’ performances were
globally close to each other, with ALP having the worst
result and CYFRA 21-1 and LDH the best. Similar
results were obtained when markers were assessed dur-
ing treatment, before cycle 2 (three to four weeks later,
Figure 3) and before cycles 3 to 4 (six to nine weeks
later, not shown).
In a univariate analysis for PFS, performance status,
number of metastatic sites and triple-negative status
were statistically significant for PFS (Table 4). At multi-
variate analysis, only performance status and triple nega-
tive tumor status were independent clinical prognostic
factors and were included in a clinical model. CTC,
LDH, CYFRA21.1, CEA and CA15.3 were statistically
significant for PFS and not ALP. When the concordance
index was calculated for each tumor marker or CTCs
added to the clinical model, all of them, except ALP,
slightly improved the performance of the clinical model.
The C-index of the clinical model (0.697) increased
from 0.71 to 0.723, except with ALP.
Changes under treatment and association with PFS
By combining marker status (elevated or not) before
cycle 1 and before cycle 2, four subgroups could be
separated for each marker. Figure 4 shows that these
early changes were highly correlated with PFS in uni-
variate analysis for all the markers; globally, patients
with non-elevated markers at both time points had
longer PFS; patients with elevated markers at both time
points had generally the worst PFS. However, even in
these groups of worst prognosis, median PFS was longer
than six months for every marker tested, suggesting that
none of these marker’s early changes can predict accu-
rately very short PFS. Concordance indexes with PFS
were C-indexCTC = 0.57 (0.51 to 0.63) (n = 201), C-
indexALP = 0.50 (0.44 to 0.56) (n = 195), C-indexCEA =
0.45 (0.38 to 0.51) (n = 157), C-indexCA15-3 = 0.50 (0.44
to 0.56) (n = 193), C-indexCYFRA21-1 = 0.57 (0.50 to
0.65) (n = 142) and C-indexLDH = 0.63 (0.55 to 0.70) (n
= 136). Again, these results showed that marker perfor-
mances were extremely close to each other.
As a spurious early rise of serum markers may occur
during the first weeks of a new chemotherapy and may
lower the above serum markers’ concordance indexes,
we also studied the changes that occur before cycle 1
and before cycles 3 to 4; Figure 5 shows that these
changes were also significant for all the markers. We
calculated the concordance indexes by combining mar-
ker status before cycle 1 and before cycle 3/4 (weeks 6
Table 1 CTC and serum marker values repartition at inclusion
Mean SD Quantile 0% Quantile 25% Quantile 50% (median) Quantile 75% Quantile 100% N
CTC 81.65 324.76 0 0 2.5 23.25 3,369 260
CA15.3 7.53 23.77 0.14 0.7 1.76 4.45 314.1 247
CEA 7.20 18.23 0.04 0.4 1 3.45 146.13 212
CYFRA21 9.01 29.51 0.1 0.65 1.95 5.25 284.54 191
LDH 1.39 2.02 0.28 0.71 0.92 1.45 25.54 220
ALP 1.056 1.00 0.26 0.58 0.79 1.06 10 241
CTC and serum markers values at inclusion repartition in percentile, mean, median range. Values for serum marker are expressed in ULNV, upper limit of the
normal value
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to 9). The concordance indexes for the five serum mar-
kers and for CTC were all between 0.61 and 0.66, with
largely overlapping 95% confidence intervals.
CTC prognostic value according to serum marker
subgroups
Finally, interaction tests have been performed to further
study if the prognostic value of baseline CTC count and
of CTC count changes under treatment were restricted
and/or different according to the different patient’s sub-
group, including serum marker subgroups (for example,
in patients with non-elevated CEA vs elevated CEA).
These tests were non significant.
Discussion
The need for novel independent prognostic factors in
metastatic breast cancer patients is much lower than the
need for dynamic blood markers, which can indicate the
treatment efficiency in a reliable and early fashion.
Serum tumor markers are an easy, quick, cheap, but
rather imprecise and sometimes misleading tool, to
monitor the treatment efficacy. However, they are
Figure 1 Boxplot of CTC and serum markers values (semi log scale), median and CI 95%.
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particularly valuable for treatment monitoring in
patients that have disease that cannot be evaluated by
radiology. CTC count by the CellSearch® system is a
validated prognostic factor at baseline, but is also used
for treatment monitoring [13-15]. This test is, however,
more expensive than serum tumor markers and has
never been directly compared with them. The IC 2006-
04 is the first large prospective study in which a com-
parison between CTC and five different serum markers
was pre-planned.
At first, our study tried to answer a recurrent issue for
medical oncologists, that is “which serum marker should
Table 2 Detection rates of elevated markers at baseline













Menopausal status NS NS P = 0.01 NS NS NS
Premenopausal 113 42% 44% 54% 44% 25% 45%
Postmenopausal 148 58% 56% 72% 45% 33% 43%
Receptor status NS P = 0.002 NS NS NS NS
Horm. positive 159 68% 58% 65% 40% 33% 46%
HER2 positive 45 60% 51% 56% 49% 32% 34%
Triple negative 54 57% 27% 74% 53% 19% 46%
Tumor grade NS P = 0.05 NS NS P = 0.03 NS
1 26 77% 76% 64% 37% 52% 48%
2 106 64% 55% 62% 43% 28% 41%
3 123 63% 45% 68% 47% 25% 45%
Performance status P = 0.003 P = 0.02 P < 10-4 P < 10-4 P = 0.001 P < 10-4
0 123 55% 42% 51% 21% 18% 29%
1 97 69% 57% 70% 58% 34% 49%
2 22 82% 53% 79% 79% 52% 71%
3 or 4 13 92% 78% 100% 100% 54% 92%
Number of metastatic
sites
P = 0.02 NS P = 0.001 P < 10-4 NS P =
0.03
< 3 155 60% 52% 55% 37% 28% 39%
≥ 3 106 71% 51% 80% 56% 31% 48%
CA 15.3 - P < 10-4 P < 10-4 P < 10-4 P < 10-4 P < 10-4
≤ ULNV 88 - 24% 54% 25% 13% 26%
> ULNV 159 - 68% 72% 56% 40% 53%
CEA - - P = 0.005 P = 0.009 P = 0.001 P =
0.03
≤ ULNV 103 - - 56% 36% 18% 35%
> ULNV 109 - - 75% 55% 38% 49%
CYFRA 21-1 - - - P < 10-4 NS P < 10-4
≤ ULNV 66 - - - 16% 23% 19%
> ULNV 125 - - - 63% 34% 56%
LDH - - - - P = 0.02 P < 10-4
≤ ULNV 121 - - - - 22% 25%
> ULNV 99 - - - - 36% 67%
ALP - - - - - P < 10-4
≤ ULNV 170 - - - - - 36%
> ULNV 71 - - - - - 65%
All population
at baseline
64% 51% 65% 45% 29% 44%
All population
before cycle 2
66% 46% 34% 43% 28% 17%
All population
before cycle 3/4
64% 40% 27% 49% 22% 13%
ULNV: upper limit of normal value. P-values were obtained by Pearson’s Chi-square test. Horm. positive: either estrogen and/or progesterone receptor positive by
immunohistochemistry on primary tumor. HER2 positive: HER2 overexpressed by immunohistochemistry or amplified by FISH in 2+ cases. Triple negative:
estrogen, progesterone and HER2 negative primary tumor. NS, non significant. Significant associations (P ≤ 0.05) are in bold.
Bidard et al. Breast Cancer Research 2012, 14:R29
http://breast-cancer-research.com/content/14/1/R29
Page 5 of 10
I ask for?” To be considered as informative and usable
for further determination under therapy, a serum mar-
ker should be elevated at baseline, before the start of
therapy. Historically, comparison between serum mar-
kers mostly used positivity rates (> ULNV) at baseline
in metastatic patients [16]. For serum markers and
CTC, incidence rates were in line with those previously
reported at first metastatic relapse [17,18], together with
the low incidence of CEA in triple-negative cancers [19].
Our study shows that repeated CTC counts are
Table 3 Percentage of patients with at least one elevated marker at baseline
Markers assessed N patients assessed % with at least 1 elevated marker
CEA CA 15-3 CYFRA 21-1 CTC
2 markers combinations
X X 239 72%
X X 240 75%
X X 257 75%
X X 225 77%
X X 206 80%
X X 231 86%
3 markers combinations
X X X 251 83%
X X X 233 86%
X X X 234 88%
X X X 234 88%
4 markers combination
X X X X 246 90%
Single marker positivity rates are given for each of the markers, Table 2.
CTC
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Figure 2 Progression-free survival (PFS) according to blood markers at diagnosis.
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informative mainly for patients who have an elevated
level at baseline (≥ 5CTC/7.5 ml), but not for patients
initially CTC negative (< 5CTC/7.5 ml), as only two of
these patients will present an increase (≥ 5CTC/7.5 ml)
during treatment (Figure 3). Due to the very small num-
ber of these patients, no conclusion can be drawn on
the prognostics of this subgroup. On the basis of base-
line positivity rate comparison, assessing only CEA and
CA 15-3, the two most commonly used breast cancer
serum markers retrieve around 75% of patients with at
least one marker elevated at baseline. Our study has
also investigated CYFRA 21-1 as a breast cancer serum
marker, which turned out to be the most commonly ele-
vated serum tumor marker (65% of patients), as already
suggested in smaller studies [20,21]. Adding either
CYFRA 21-1 or CTC to this CEA and CA 15-3 combi-
nation further increases this percentage to around 90%
of patients, but assessing the full four-marker panel
(CEA, CA 15-3, CYFRA 21-1 and CTC) did not further
improve the overall positivity rate. Among the different
markers tested, a drop in positivity rates between base-
line and cycle 3/4 was mostly observed for CTC and
CYFRA 21-1: 44 to 13% and 65 to 27% respectively
(Table 2).
We showed that serum markers and CTC positivity
were highly correlated with other known clinical prog-
nostic factors, such as poor performance status or the
high number of metastatic sites. Interestingly, neither
serum markers nor CTC detection were correlated with
immunohistological subtypes (hormone receptors-posi-
tive, HER2-positive or triple-negative breast cancers).
Unsurprisingly, each of the markers tested had a signifi-
cant impact on PFS in univariate analysis. Multivariate
analyses, including serum markers, CTC and known
clinical prognostic factors, have been reported pre-
viously: CTC and CEA were the two blood markers
independently associated with PFS, whereas CTC count
was the only blood marker independently associated
with OS [9].
Here, by comparing the early and late changes of five
blood markers together with CTC changes for PFS
prediction, we showed no clear superiority of CTC
over the other serum markers. This result was, how-
ever, not the primary endpoint of our study, and the
statistical power of these analyses may still be dis-
cussed, although performed in more than 200 patients.
For this analysis, we used the “prognosis-optimized”
threshold of ≥ 5 CTC/7.5 ml, which was initially
CTC
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Figure 3 PFS according to blood markers before cycle 2.
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defined as the best dichotomizing threshold for PFS
and OS prediction by CTC at baseline and under treat-
ment [7]. Contrarily, for serum tumor markers, the
upper limits of normal values (ULNV) were historically
defined by healthy-donor analyses, and no cut-off has
been optimized previously for survival prediction. In
this study, it was pre-analytically planned to use ULNV
as the positivity threshold at both baseline and before
cycle 2 and, as for CTC counts, to divide the popula-
tion into four subgroups according to the marker at
baseline and before cycle 2. Other models may have
been used for serum markers, in order to take into
account the relative changes of elevated marker (for
example, 50% decrease between baseline at cycle 2...),
but testing all the possibilities for serum marker ana-
lyses would have led to multiple testing biases favoring
serum markers over CTC.
Conclusion
Finally, the IC 2006-04 study suggests that CTC count
should not be considered alone, but should be put into
the current clinical context of metastatic breast cancer.
We previously demonstrated that CTC, but not serum
markers, has an independent prognostic value in multi-
variate analysis. This prognostic value did not interact
with any tested subgroup. However, when focusing on
the different blood markers assessable for PFS predic-
tion before and during treatment, we report here that
there is no clear superiority of CTC count over serum
markers. Markers predicting or monitoring treatment
efficiency are much more needed for patients with meta-
static breast cancer than prognostic serum markers. A
further prospective comparative study would be required
to obtain a definite conclusion with a predefined statisti-
cal power. As, to our knowledge, no such study is
ongoing, we believe that the IC 2006-04 will remain the
largest prospective study with a CTC/serum marker
comparison. The interest of implementing CTC count
into the routine management of metastatic breast cancer
chemotherapy will be finally assessed in the two ongoing
randomized trials SWOG500 (USA) and CirCe01
(France).






































































































Univariate analysis using hazard ratios and 95% CI for PFS for each clinical characteristic in the first column. Multivariate analysis for clinical parameters (second
column) (Multiv. clin) Contribution for each tumor marker or CTCs to clinical model (Multiv.clin + serum marker) Last line: Concordance indexes for PFS for
clinical model including all the clinical characteristics and for each tumor marker or CTCs.
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C1 < N C2 < N
C1 >= N C2 < N
C1 < N C2 >= N
C1 >= N C2 >= N
p = 0.0016
Figure 4 PFS and marker changes between baseline and cycle 2.
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C1 < N C3C4 < N
C1 >= N C3C4 < N
C1 < N C3C4 >= N
C1 >= N C3C4 >= N
p = 0.0229
Figure 5 PFS and marker changes between baseline and cycles 3 to 4.
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